Halozyme Therapeutics (HALO) Cash & Current Investments (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash & Current Investments data on file, last reported at $318.6 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $318.6 million, down 57.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $318.6 million (down 57.4% YoY), and the FY2025 annual result was $142.8 million, down 76.04% from the prior year.
• Cash & Current Investments rose to $318.6 million in Q1 2026 per HALO's latest filing, from $142.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $786.1 million in Q1 2022 and troughed at $142.8 million in Q4 2025.
• A 5-year average of $457.7 million and a median of $463.5 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments soared 81.97% in 2023, then tumbled 76.04% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $362.8 million in 2022, then dropped by 7.39% to $336.0 million in 2023, then jumped by 77.4% to $596.1 million in 2024, then plunged by 76.04% to $142.8 million in 2025, then surged by 123.09% to $318.6 million in 2026.
• Business Quant data shows HALO's Cash & Current Investments at $318.6 million in Q1 2026, $142.8 million in Q4 2025, and $702.0 million in Q3 2025.